CAR-M therapy LIB820 may deplete disease-driving B-cells in MS and other autoimmune diseases without severe side effects, new ...

Imaging CRO Qureight will use its end-to-end imaging technology and services in a clinical trial analysing diffuse cutaneous Systemic Sclerosis (dcSSc). SSc is a complex disease characterised by ...

More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, ...

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a ...

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patient ...

Background Systemic sclerosis, also known as scleroderma, is a complex, multi-organ disease which causes substantial and progressive fibrosis of the skin and internal organs, including the heart and ...

Scleroderma is an autoimmune condition that causes the skin to become tight and hard. This can change facial appearance, such as the mouth becoming smaller, and affect internal organs. With ...

Scleroderma is a rare autoimmune disease involving an overproduction of the protein collagen. Linear scleroderma usually begins as a streak of hardened, waxy, discolored skin on the forehead, an arm, ...

Changes in NAWM and NAGM are crucial in MS progression, challenging the traditional lesion-centric model. Subtle alterations in myelin integrity, immune cell function, and neuronal connectivity ...

Several factors were associated with increased pain among patients with systemic sclerosis, including the pain type, pain location, and disease subtype. Nearly all patients with systemic sclerosis ...